natgillin/translations-raw huggingface dataset:
• atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin.
• ki trpijo za atrijsko fibrilacijo (nerednim hitrim krčenjem zgornjih srčnih preddvorov), pri katerih je treba zdravilo dajati skupaj z aspirinom.
• a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots).
• ki imajo akutni koronarni sindrom, pri katerem je treba zdravilo dajati skupaj z aspirinom (drugim zdravilom za preprečevanje krvnih strdkov).
The Agency recommended that Clopidogrel Krka be approved for use in the EU.
Priporočila je, da se zdravilo odobri za uporabo v EU.
Why is Clopidogrel Krka approved?
Zakaj je bilo zdravilo Klopidogrel Krka odobreno?
The active substance in Clopidogrel Krka, clopidogrel, is an inhibitor of platelet aggregation.
Zdravilna učinkovina zdravila Klopidogrel Krka, klopidogrel, je zaviralec agregacije trombocitov.
How has Clopidogrel Krka been studied?
Kako je bilo zdravilo Klopidogrel Krka raziskano?
How is Clopidogrel Krka used?
Kako se zdravilo Klopidogrel Krka uporablja?
Clopidogrel Krka contains the active substance clopidogrel.
Zdravilo Klopidogrel Krka vsebuje zdravilno učinkovino klopidogrel.
How does Clopidogrel Krka work?
Kako zdravilo Klopidogrel Krka deluje?
Clopidogrel Krka can only be obtained with a prescription.
Predpisovanje in izdaja zdravila Klopidogrel Krka je le na recept.
The joint PASS final study report submitted by the MAHs complies with their obligation to perform a PASS to evaluate the effectiveness of the risk minimisation activities as imposed during the Article 107i procedure EMA/H/A-107i/1357 for cyproterone/ethinylestradiol containing products.
Končno poročilo študije PASS, ki so jo predložili imetniki dovoljenj za promet, je v skladu z obveznostjo izvajanja PASS za ocenitev učinkovitosti ukrepov zmanjševanja tveganj, naloženih v okviru postopka člena 107i EMA/H/A-107i/1357 za zdravila, ki vsebujejo ciproteron/etinilestradiol.
Therefore, in view of available data regarding the joint PASS final study report, the PRAC Rapporteur considered that changes to the conditions of the marketing authorisation were warranted.
Zato na podlagi razpoložljivih podatkov glede končnega poročila študije PASS, poročevalec odbora PRAC meni, da so potrebne spremembe pogojev dovoljenj za promet z zdravili.
Grounds for the variation to the terms of the Marketing Authorisation(s) On the basis of the scientific conclusions for the results of the study for the medicinal product(s) containing the active substance cyproterone/ethinylestradiol and concerned by the PASS final report , the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) mentioned above is unchanged subject to the proposed changes to the product information.
Podlaga za priporočilo spremembe pogojev dovoljenja (dovoljenj) za promet z zdravilom Na podlagi znanstvenih zaključkov rezultatov študije za zdravila, ki vsebujejo ciproteron/etinilestradiol in jih zadeva končno poročilo PASS, skupina CMDh meni, da je razmerje med koristjo in tveganjem zgoraj navedenih zdravil nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
Further information on Renvela can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/renvela.
Nadaljnje informacije za zdravilo Renvela so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/renvela.
• adults and children from 6 years of age with chronic (long-term) kidney disease.
• odraslih in otrocih, starejših od šest let, s kronično (dolgotrajno) boleznijo ledvic.
The European Medicines Agency therefore concluded that Renvela's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Renvela večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of Renvela?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Renvela?
Renvela received a marketing authorisation valid throughout the EU on 10 June 2009.
Za zdravilo Renvela je bilo 10. junija 2009 izdano dovoljenje za promet, veljavno po vsej EU.
Other information about Renvela
Druge informacije o zdravilu Renvela
Renvela should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Zdravilo Renvela je treba uporabljati sočasno z drugimi zdravili, na primer z dodatki kalcija in vitamina D, da se prepreči razvoj bolezni kosti.
As for all medicines, data on the use of Renvela are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Renvela stalno spremljajo.
Renvela must not be taken on an empty stomach and patients should keep to their prescribed diets.
Zdravilo Revela se ne sme jemati na prazen želodec, bolniki pa morajo upoštevati predpisano dieto.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Renvela have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Renvela upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Renvela is available as tablets (800 mg) and as powder (0.8 g, 1.6 g and 2.4 g) in a sachet to be taken 3 times a day with meals.
Zdravilo Renvela je na voljo v obliki tablet (800 mg) in praška (0,8 g, 1,6 g in 2,4 g) in se jemlje trikrat na dan z obroki.
Side effects reported with Renvela are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Renvela, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Renvela (sevelamer carbonate) EMA/357790/2019
Renvela (sevelamerijev karbonat) EMA/357790/2019
For more information about using Renvela, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Renvela glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
An overview of Renvela and why it is authorised in the EU
Pregled zdravila Renvela in zakaj je odobreno v EU
When taken with meals, it attaches in the gut to phosphate from food, thereby preventing the phosphate from being absorbed into the body and helping reduce phosphate levels in the blood.
Ko se vzame s hrano, se v črevesju veže na fosfat iz hrane, kar preprečuje njegovo absorpcijo v telo in prispeva k zmanjšanju ravni fosfata v krvi.
The most common side effects with Renvela (which may affect more than 1 in 10 people) are nausea (feeling sick), vomiting, upper abdominal (belly) pain and constipation.
Najpogostejši neželeni učinki zdravila Renvela (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) so navzeja (siljenje na bruhanje), bruhanje, bolečine v zgornjem predelu trebuha in zaprtje.
In a third main study in 49 adults who were not on dialysis, Renvela reduced phosphate levels from 2.0 mmol/l to 1.6 mmol/l.
V tretji glavni študiji pri 49 odraslih, ki niso bili na dializi, je zdravilo Renvela znižalo ravni fosfata z 2,0 mmol/l na 1,6 mmol/l.
What benefits of Renvela have been shown in studies?
Kakšne koristi je zdravilo Renvela izkazalo v študijah?
Why is Renvela authorised in the EU?
Zakaj je bilo zdravilo Renvela odobreno v EU?
In two main studies in 110 adults with kidney disease who were on dialysis, Renvela brought phosphate levels down to around 1.5-1.6 mmol/l (which is within or close to the normal range) and was as effective as another authorised medicine Renagel.
V dveh glavnih študijah pri 110 odraslih z obolenjem ledvic, ki so bili na dializi, je zdravilo Renvela znižalo ravni fosfata na približno 1,5-1,6 mmol/l (kar je znotraj oziroma blizu normalnega razpona) in je bilo enako učinkovito kot drugo, že odobreno zdravilo, in sicer zdravilo Renagel.
What are the risks associated with Renvela?
Kakšna tveganja so povezana z zdravilom Renvela?
Renvela (sevelamer carbonate)
Renvela (sevelamerijev karbonat)
Renvela is a medicine used to control hyperphosphataemia (high blood phosphate levels) in:
Renvela je zdravilo, ki se uporablja za nadzor hiperfosfatemije (visoke ravni fosfata v krvi) pri:
What is Renvela and what is it used for?
Kaj je zdravilo Renvela in za kaj se uporablja?
Finally, a main study also showed that Renvela was effective at lowering phosphate levels in 100 children: children who took Renvela had a greater reduction in phosphorous (0.87 mg/dl) than those taking placebo (a dummy treatment) who had a rise in phosphorous of 0.04 mg/dl.
V še eni glavni študiji pri 100 otrocih so ugotovili, da je zdravilo Renvela učinkovito pri zniževanju ravni fosfata, saj se je raven fosforja pri otrocih, ki so jemali to zdravilo, zmanjšala bolj (0,87 mg/dl) kot pri tistih, ki so jemali placebo (zdravilo brez učinkovine), pri katerih se je vrednost fosforja zvišala za 0,04 mg/dl.
The dose to take depends on the patient's level of blood phosphate and, in case of children, their height and weight.
Odmerek je odvisen od bolnikove ravni fosfata v krvi, pri otrocih pa od telesne višine in mase.
Studies show that Renvela is effective at reducing levels of blood phosphate in patients with hyperphosphataemia, and its side effects are considered manageable.
V študijah so ugotovili, da je zdravilo Renvela učinkovito pri zniževanju ravni fosfata v krvi pri bolnikih s hiperfosfatemijo, njegovi neželeni učinki pa se štejejo za obvladljive.
How does Renvela work?
Kako zdravilo Renvela deluje?
How is Renvela used?
Kako se zdravilo Renvela uporablja?
Renvela has been shown in studies to be effective at lowering levels of blood phosphate in patients with hyperphosphataemia.
V študijah so dokazali, da je zdravilo Renvela učinkovito pri zniževanju ravni fosfata v krvi pri bolnikih s hiperfosfatemijo.
The active substance in Renvela, sevelamer carbonate, is a phosphate binder.
Učinkovina v zdravilu Renvela je fosfatni vezalec sevelamerijev karbonat.
Renvela must not be used in people with low blood phosphate levels or with bowel obstruction (a blockage in the gut).
Zdravilo se ne sme uporabljati pri ljudeh s hipofosfatemijo (nizko koncentracijo fosfatov v krvi) ali zaporo črevesa.
For the full list of side effects with Renvela, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Renvela, glejte navodilo za uporabo.
- Are you exercising more than usual?
- Ali ste telesno bolj dejavni kot običajno?
• you have an infection or illness (especially diarrhoea or vomiting);
• imate okužbo ali zbolite (še posebej driska ali bruhanje);
ATC Code: A10A D04.
Oznaka ATC: A10AD04.
Are you exercising more than usual?
− Ali ste telesno bolj dejavni kot običajno?
Patients with diabetes should be advised to inform their doctor if they are pregnant or are contemplating pregnancy.
Bolnicam z diabetesom je treba svetovati, naj obvestijo zdravnika, če zanosijo ali načrtujejo zanositev.
Detailed information can be found in the following table.
Podrobne informacije so podane v spodnji tabeli.
Please tell your doctor, if you are taking or have recently taken any other medicines, including medicines obtained without a prescription (see section “Warnings and precautions”).
Obvestite zdravnika, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta (glejte poglavje “Opozorila in previdnostni ukrepi”).
In one clinical study there was a small (0.38 mmol/l) increase in blood glucose levels at night (3a.m.
V eni klinični študiji je bil majhen (0.38 mmol/l) porast ravni glukoze merjene ponoči
• there is a change in your need for insulin; or
• se pri vas spremenijo potrebe po insulinu; ali
• you have trouble with your kidneys or liver which gets worse.
• imate težave z ledvicami ali jetri in se stanje poslabša.
• you exercise or work too hard just before or after a meal;
• ste telesno preveč dejavni ali preveč delate tik pred obrokom ali po njem;
Now inject air into the Humalog vial in the same manner, but do not withdraw the needle.
Zdaj injicirajte zrak v vialo zdravila Humalog na enak način, vendar ne izvlecite igle.
The expiry date refers to the last day of that month.
Rok uporabnosti se izeče na zadnji dan navedenega meseca.
Avoidance of medication errors
Izogibanje napakam pri odmerjanju zdravila
• You should also tell your doctor, pharmacist or diabetes nurse if you are planning to go abroad.
• Zdravnika, farmacevta ali medicinsko sestro v diabetološki ambulanti obvestite tudi, če načrtujete potovanje v tujino.
Paediatric population Humalog can be used in adolescents and children (see section 5.1).
Zdravilo Humalog se lahko uporablja pri mladostnikih in otrocih (glejte poglavje 5.1).
• eating a lot more than your diet allows; or
• pojedli ste veliko več, kot predpisuje vaša dieta; ali
NAME OF THE MEDICINAL
IME ZDRAVILA
Step 2: (For HUMALOG suspensions cloudy insulins only)
Korak 2: (samo za motne insuline v suspenziji HUMALOG)
If necessary, Humalog may also be administered intravenously, for example: for the control of blood glucose levels during ketoacidosis, acute illnesses or during intra and post operative periods.
Po potrebi se zdravilo Humalog lahko injicira tudi intravensko, na primer za nadzor ravni glukoze v krvi med ketoacidozo, med akutno boleznijo ali med operacijami in po njih.
The amount of insulin you need usually falls during the first three months of pregnancy and increases for the remaining six months.
Količina insulina, ki ga potrebujete, običajno v prvih treh mesecih nosečnosti upade, v naslednjih šestih mesecih pa se poveča.
Humalog BASAL has an activity profile that is very similar to that of a basal insulin (NPH) over a period of approximately 15 hours.
Humalog BASAL ima profil delovanja zelo podoben bazalnemu insulinu (NPH) v obdobju približno 15 ur.
- HUMALOG suspensions - cloudy insulins - should look white after mixing.
- Suspenzije HUMALOG - motni insulini - morajo biti po mešanju bele barve.
Time (hr)
Čas (ure)
You should never mix Humalog with insulins produced by other manufacturers or animal insulins.
Nikoli pa ne smete mešati zdravila Humalog z insulini drugih izdelovalcev ali z živalskimi insulini.
• Additional risk minimisation measures (Humalog 200 units/ml)
• Dodatni ukrepi za zmanjševanje tveganj (Humalog 200 enot/ml)
The MAH shall ensure that healthcare professionals are informed that all patients who have been prescribed Humalog should be trained on the correct use of the pre-filled pen before prescribing or dispensing Humalog.
Imetnik dovoljenja za promet z zdravilom bo zagotovil, da bodo zdravstveni delavci obveščeni, da morajo biti vsi bolniki, ki jim je bilo predpisano zdravilo Humalog, usposobljeni za pravilno uporabo napolnjenega peresnika, preden jim bo zdravilo Humalog predpisano ali izdano.
• Humalog is now available in 2 strengths
• Zdravilo Humalog je zdaj na voljo v 2 jakostih.
• Your doctor will tell you if you have to mix Humalog with one of the human insulins.
• ZZdravnik vam bo povedal, ali morate zdravilo Humalog mešati s katerim od humanih insulinov.
If the therapeutic regimen requires the injection of basal insulin and Humalog at the same time, the two can be mixed in the syringe.
Če režim zdravljenja zahteva sočasno injiciranje bazalnega insulina in zdravila Humalog, ju lahko zmešate v injekcijski brizgi.
In two 8-month open label crossover studies, type 2 diabetes patients who were either new to insulin therapy or already using one or two injections of insulin, received 4 months of treatment with Humalog Mix25 (used twice daily with metformin) and insulin glargine (used once daily with metformin) in a randomised sequence.
V dveh 8-mesečnih, odprtih, navzkrižnih študijah, so bolniki z diabetesom tipa 2, ki so bodisi začeli zdravljenje z insulinom ali pa so že uporabljali eno ali dve injekciji insulina, 4 mesece v naključnem zaporedju prejemali zdravljenje z zdravilom Humalog Mix25 (dvakrat na dan z metforminom) in insulinom glargin (enkrat na dan z metforminom).
• The number of half units (0.5 units) is shown in the dose window of your pen.
• Število polovičnih enot (0,5 enot) je prikazano v okencu za prikaz odmerka vašega peresnika.
The number of units are displayed in the dose window, always check this before your injection.
Število enot je prikazano v okencu za prikaz odmerka, to morate vedno preveriti, preden si daste injekcijo.
This medicinal product should not be mixed with any other insulin or any other medicinal product.
Tega zdravila ne smemo mešati z nobenim drugim insulinom ali z drugim zdravilom.
• It is normal to see a small amount of insulin left in the Pen that you cannot inject.
• Povsem normalno je, da v peresniku vidite majhno količino preostalega insulina, ki ga ni mogoče vbrizgati.
• Label: White with an orange colour bar and orange-to-yellow and burgundy colour band
• Oznaka: bela z oranžno vrstico in oranžnorumenim in temno rdečim barvnim trakom
INSTRUCTIONS ON USE (To open, lift here and pull) CARTON HAS BEEN OPENED
NAVODILA ZA UPORABO Če hočete odpreti, dvignite tukaj in potegnite ŠKATLA JE BILA ODPRTA
Check the appearance of the insulin.
• Preverite videz insulina.
10 ml Vial: Pack of 1.
10-mililitrske viale: pakiranja po 1.
This rapid onset of activity allows a Humalog injection to be given very close to mealtime.
Ta hitri začetek delovanja omogoča, da si je injekcijo zdravila Humalog mogoče dati časovno zelo blizu obroka.
Other forms of Humalog 100 units/ml are available if this is necessary.
Na voljo so druge oblike zdravila Humalog 100 enot/ml, če je to potrebno.
Humalog is suitable for use in adults and children.
Zdravilo Humalog je primerno za odrasle in otroke.
The MAH shall provide a Dear Healthcare Professional Letter (DHPC) and patient communication prior to launch targeting all physicians and nurses who are expected to be involved in the treatment and management of diabetic patients and, where required, all pharmacists who are expected to dispense Humalog.
Imetnik dovoljenja za promet z zdravilom bo pred dajanjem na trg oblikoval neposredno obvestilo zdravstvenim delavcem (DHPC) in informacije za bolnike, ki bodo posredovani vsem zdravnikom in medicinskim sestram, za katere se pričakuje, da bodo vključeni v zdravljenje in obravnavo bolnikov s sladkorno boleznijo ter, po potrebi, vsem farmacevtom, za katere se pričakuje, da bodo izdajali zdravilo
• Humalog should not be used outside of the pre-filled pen device
• Zdravila Humalog se ne sme uporabljati izven napolnjenih peresnikov.
Humalog is also indicated for the initial stabilisation of diabetes mellitus.
Zdravilo Humalog je indicirano tudi za začetno stabilizacijo diabetesa.
Please make sure that Humalog or Lilly cartridges are mentioned in the leaflet accompanying your pen.
Prosimo, preverite, da so vložki zdravila Humalog ali Lilly omenjeni v navodilih za uporabo, priloženih vašemu injekcijskemu peresniku.
Only your physician can administer Humalog by the intravenous route.
Samo zdravnik vam lahko da zdravilo Humalog intravensko.
It may cause a rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating.
Povzroči lahko izpuščaj po vsem telesu, težko dihanje, piskanje v pljučih, padec krvnega tlaka,
This rapid onset of activity allows a Humalog injection (or, in the case of administration by continuous subcutaneous infusion, a Humalog bolus) to be given very close to mealtime.
Ta hitri začetek delovanja omogoča, da si je injekcijo zdravila Humalog (ali bolus zdravila Humalog v primeru dajanja z neprekinjeno subkutano infuzijo) mogoče dati časovno zelo blizu obroka.
The DHPC and patient communication are aimed at increasing awareness about the fact that Humalog is now available in two strengths and describing key differences in the design of the packages and the pre-filled pen devices to minimise the risk of medication errors and mix up between the two different strengths of Humalog.
Namen neposrednega obvestila zdravstvenim delavcem (DHPC) in informacij za bolnike je izboljšanje informiranosti o dejstvu, da je zdravilo Humalog zdaj na voljo v dveh jakostih in opis ključnih razlik v zasnovi pakiranj in napolnjenih peresnikov za zmanjšanje tveganj za napake pri zdravljenju in nenamerno zamenjavo dveh različnih jakosti zdravila Humalog.
For example if you do need to inject a mixture, draw the Humalog into the syringe before the long acting insulin.
Na primer, če si morate injicirati mešanico, potegnite zdravilo Humalog v injekcijsko brizgo pred insulinom z dolgotrajnim delovanjem.
• taking less insulin than your doctor tells you to;
• vzeli ste manj insulina, kot vam ga je predpisal zdravnik;
Patients who are blind or have poor vision must be instructed to always get help/assistance from another person who has good vision and is trained in using the insulin device.
Bolnikom, ki so slepi ali slabovidni, je treba dati navodila, naj vedno poiščejo pomoč osebe, ki dobro vidi in je usposobljena za uporabo pripomočka za dajanje insulina.
empagliflozin, DPP-4-inhibitors like sitagliptin or saxagliptine, ),
empagliflozin, inhibitorji DPP-4, kot sta sitagliptin ali saksagliptin);
If you get worse and your breathing is shallow and your skin gets pale, tell your doctor at once.
Če se vam počutje poslabša in postane dihanje plitvo in koža bleda, nemudoma pokličite zdravnika.
Changes in strength, brand (manufacturer), type (regular/soluble, NPH/isophane, etc.), species (animal, human, human insulin analogue), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage.
V primeru spremembe jakosti, blagovne znamke (izdelovalca), tipa (običajni/topni, NPH/izofan itd.), vrste (živalski, humani, analog humanega insulina) in/ali načina izdelave (s pomočjo rekombinantne DNA v primerjavi z insulinom živalskega izvora) bo morda treba spremeniti odmerjanje insulina.
If repeated or severe low blood glucose levels occur consider the need to reduce or stop an insulin infusion.
Če imate pogoste ali hude epizode nizke ravni glukoze v krvi, premislite, ali bi bilo morda treba zmanjšati ali prenehati z infuzijo insulina.
• If you change the type of insulin you use (for example from a human or animal insulin to a Humalog product), you may have to take more or less than before.
• Pri prehodu na drugo vrsto insulina (na primer prehod s humanega ali živalskega insulina na zdravilo Humalog) boste morda potrebovali več ali manj insulina kot prej.
Insulin requirements may be reduced in patients with hepatic impairment due to reduced capacity for gluconeogenesis and reduced insulin breakdown; however, in patients with chronic hepatic impairment, an increase in insulin resistance may lead to increased insulin requirements.
Okvarjeno delovanje jeter Pri bolnikih z okvarjenim delovanjem jeter so lahko potrebe po insulinu zmanjšane zaradi zmanjšane zmožnosti glukoneogeneze in zmanjšane razgradnje insulina; vendar pa lahko pri bolnikih s kronično okvaro jeter povečanje odpornosti na insulin povzroči povečane potrebe po insulinu.
If this happens to you, tell your doctor.
Če tako reakcijo opazite pri sebi, povejte svojemu zdravniku.
Pack of 1, 2 and 5
Pakiranja po 1, 2 in 5
Insulin requirements and dosage adjustment Insulin requirements may be increased during illness or emotional disturbances.
Potrebe po insulinu in prilagajanje odmerkaPotrebe po insulinu se lahko povečajo v času bolezni ali čustvenih težav.
A. Hypoglycaemia
A. Hipoglikemija
• Store the Pen you are currently using at room temperature up to 30°C and away from dust, food and liquids, heat and light.
• Peresnik, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi do 30 °C in ga zaščitite pred prahom, hrano in tekočinami, vročino in svetlobo.
Do not use the pen to administer Humalog by a different way.
Peresnika ne smete uporabljati za dajanje zdravila Humalog na drug način.
- Labels:
- Oznake:
• The dose can be corrected by turning the Dose Knob in either direction until the correct dose lines up with the Dose Indicator.
• Odmerek je mogoče popraviti z obračanjem gumba za odmerjanje v obe smeri, dokler se pravi odmerek ne poravna s kazalnikom odmerka.